These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22327134)

  • 21. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease.
    Allen JA; Greenberg SA; Amato AA
    Muscle Nerve; 2009 Oct; 40(4):643-7. PubMed ID: 19670319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor.
    Ammer J; Prantl L; Holler B; Landfried K; Wolff D; Karrer S; Andreesen R; Holler E
    Bone Marrow Transplant; 2012 Oct; 47(10):1368-9. PubMed ID: 22343673
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of a severe extensive cutaneous chronic GVHD after allo-HSCT using glycerolyzed skin allografts and cultured epidermis from the same donor.
    Crocchiolo R; Nicolini FE; Sobh M; Ducastelle-Lepretre S; Labussiere H; Dubois V; Auxenfans C; Mojallal A; Damour O; Braye F; Michallet M
    Bone Marrow Transplant; 2011 Aug; 46(8):1153-5. PubMed ID: 21042311
    [No Abstract]   [Full Text] [Related]  

  • 26. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
    Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
    Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isomorphic cutaneous graft-versus-host disease reaction after ultraviolet exposure: clinical, histological and direct immunofluorescence studies of four allo-transplanted patients.
    Vassallo C; Brazzelli V; Zecca M; Locatelli F; Alessandrino PE; Borroni G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):913-8. PubMed ID: 19586515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation.
    Kotani A; Hori T; Fujita T; Kambe N; Matsumura Y; Ishikawa T; Miyachi Y; Nagai K; Tanaka Y; Uchiyama T
    Bone Marrow Transplant; 2007 Mar; 39(6):373-5. PubMed ID: 17277792
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.
    Lo JW; Leung AY; Huang XR; Lie AK; Metz C; Bucala R; Liang R; Lan HY
    Bone Marrow Transplant; 2002 Sep; 30(6):375-80. PubMed ID: 12235522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation.
    Leithauser M; Kahl C; Aepinus C; Prall F; Maruschke M; Riemer H; Wolff D; Jost K; Hilgendorf I; Freund M; Junghanss C
    Transpl Infect Dis; 2010 Jun; 12(3):251-7. PubMed ID: 20002357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia.
    Lee JH; Lee JH; Kim DY; Yun SC; Kim SD; Choi Y; Lee YS; Kang YA; Jeon MJ; Seol M; Lee KH
    Eur J Haematol; 2011 Aug; 87(2):172-81. PubMed ID: 21599753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Kojima R; Kami M; Kim SW; Murashige N; Kishi Y; Hori A; Imataki O; Hamaki T; Sakiyama M; Masuo S; Fujisawa Y; Makimoto A; Heike Y; Tanosaki R; Takaue Y
    Bone Marrow Transplant; 2003 Aug; 32(4):439-42. PubMed ID: 12900783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.